Leverage patent expiry to launch products

Patent expiry arbitrage is a market entry strategy that exploits the moment legal protection on a proven product lapses, allowing new entrants to manufacture, improve, or rebrand the same underlying technology — typically at lower cost or with superior distribution.

Every patent is a ticking clock. For up to 20 years, a patent grants its holder a legal monopoly — the right to exclude competitors from making, using, or selling a specific invention. During that window, the patent holder captures monopoly rents: pricing power unchecked by competition, margins that reflect exclusivity rather than cost of production. When the clock runs out, that monopoly evaporates overnight. The underlying technology enters the public domain, and anyone can manufacture it.

The cognitive shift this framework demands is simple: stop looking for things to invent and start looking for things that are about to become unprotected. The patent system itself is your deal flow engine. Every granted patent has a public expiration date. The FDA publishes lists of drug patents approaching expiry through its Orange Book. The USPTO maintains searchable databases. The information is free, the timing is predictable, and the demand has already been validated — often by billions of dollars in annual sales.

The underlying principle is that patent-protected products create artificially suppressed supply. Consumers who want the product but can't afford the monopoly price represent latent demand. When the patent expires, that demand doesn't need to be created — it needs to be served. The first movers who are ready with manufacturing capacity, regulatory approvals, and distribution on the day the patent lapses capture a disproportionate share of that demand release.

This is most visible in pharmaceuticals, where generic drugs routinely capture 80–90% of a branded drug's volume within a year of patent expiry. But the principle applies anywhere patents create pricing power: semiconductors, industrial chemicals, medical devices, consumer electronics components, agricultural biotechnology, and increasingly, software-adjacent hardware. The Hatch-Waxman Act of 1984 codified this dynamic in pharma by creating an abbreviated pathway for generic drug approval, but the strategic logic predates the legislation. Wherever a patent expires on a product with proven demand, the opportunity exists.

The mechanics vary by industry, but the playbook has three constants: identify the expiring protection, prepare your supply chain and regulatory approvals in advance, and launch the moment the window opens. The companies that win are not the ones who notice the expiry — that information is public. They're the ones who spent 18–36 months preparing so they could ship on Day One.